PATENT ATTORNEY DOCKET NO.: 060490-5001-US



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Yong YAO, et al.	
Application No. 10/087,217	) Group Art Unit: 1645
Filed: March 4, 2002	) Examiner: Unassigned
For: NOVEL CELL-BASED ASSAYS FOR G-PROTEIN COUPLED RECEPTOR-MEDIATED ACTIVITIES	) ) )

# SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Commissioner of Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window Crystal Plaza Two, Lobby, Room 1B03 Arlington, VA 22202

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Copies of the listed documents are attached.

Each document listed in this Information Disclosure Statement was cited in a communication dated July 16, 2003 (copy attached) from the International Searching Authority in a counterpart foreign application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document. Applicants further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Application No.: 10/087,217 Attorney Docket No.: 060490-5001-US

Page 2

**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Bonnie Weiss McLeod

Reg. No. 43,255

Date: November 12, 2003

CUSTOMER NO. 009629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 739-3000 Telephone
(202) 739-3001 Facsimile

(PW FORM	PAT-	nent of Commerce 1449) rademark Office	4	O I	PE. 2003	\$\\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\		Dkt. No.	60490-5001-US						
INFORMA BY APPL		N DISCLOSUR	E ST	<b>WAY PAR</b>	ENT?			<del></del>	ong YAO, et al						
DIAIIL								Appln. No.:	10/087,217						
									March 4, 2002	<u> </u>					
Date: Nove	embe	r 12, 2003	Page	1	of	1	]		Unassigned)l		up Art U	 nit: 1	645		
		OCUMENTS		<u> </u>	<u> </u>	<u> </u>		· · · · · · · · · · · · · · · · · · ·							
Examiner' s Initials*		Document Number		Date MM/YYYY		Name (Family Name		of First Inventor)		Clas	s Sub Clas	s	Filing Date (if appropriate)		
	AR														
	BR														
	CR														
FOREIGN	PATI	ENT DOCUMEN	TS								English		Translat		
		Document Number	Date MM/Y	Coun		ntry Inve		ntor Name			Abstract	bstract		Readily Available	
											Enclosed	No	Enclose	No	
	DR														
	ER													$\prod$	
	FR														
OTHER (Ir	ncludi	ng in this order A	uthor,	Title,	Period	dical Name	e, Dat	e, Pertinent	Pages, etc.)						
	GR	McAllister et al., 291(2):618-626			of Ph	armacolog	gy and	d Experiment	tal Therapeutic	5,	x				
	HR										х				
	IR	Lee et al., Journal of Neurochemistry, 72(1):58-65 (1999)								X					
	JR	Oz et al., Molecular Pharmacology, 54:1106-1112 (1998)								X					
	KR	International Searching Authority, PCT/US02/34122								X					
	LR			<del>.</del>								<u> </u>		$\downarrow$	
	MR											<u> </u>		丄	
	NR														
	OR											<u> </u>	<u> </u>		
	PR											Ļ	ļ <u>.</u>	ــــــــــــــــــــــــــــــــــــــ	
	QR											<u> </u>	ļ	$oldsymbol{oldsymbol{\perp}}$	
	RR										ļ	ऻ	<b></b>	igspace	
	SR											<u> </u>		4_	
	TR											<u> </u>	<del> </del>	+	
	UR											ļ	ļ <b>.</b>	+-	
	VR	<u> </u>						T				<u> </u>	<u> </u>	<u></u>	
Exam								Date Consid							
*EXAMINE	R:	Initial if citation cor	nsidere	d. whe	ther or	not citation	is in d	conformance v	with MPEP § 609	. Drav	v line thro	ugh d	citation if	not	

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if no in conformance and not considered. Include copy of this form with next communication to Applicant.



GAU -16:45-Image 16:46

**PATENT** 

Attorney Docket No.: 060490-5001-US

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Yong YAO, et al.	, )
Application No.: 10/087,217	) Group Art Unit: 1645
Filed: March 4, 2002	) Examiner: Unassigned.
For: NOVEL CELL-BASED ASSAYS FOR G-PROTEIN COUPLED RECEPTOR-MEDIATED ACTIVITIES	) ) )
Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window Crystal Plaza Two, Lobby, Room 1B03 Arlington, VA 22202	
Sir:	

#### TRANSMITTAL FORM

1. Transmitted herewith is:

Information Disclosure Statement
Form PTO-1449, with 4 references and International Searching Authority included.

## 2. Extension of Time

The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136(a) apply.

Applicant believes that no extension of time is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

	Applicant petitions for an extension of time, the fees for which are set out in 37 C.F.R. § 1.17(a), for the total number of months checked below:								
	Total Months Requested	Fee for Extension	[Fee for Small Entity]						
	one month two months three months four months	\$ 110.00 \$ 420.00 \$ 950.00 \$ 1,480.00	\$ 55.00 \$ 210.00 \$ 475.00 \$ 740.00						
	Extension of time fee due with this request: \$								
·	If an additional extension of time is required, please consider this a Petition therefor.								
	An extension formonths has already been secured and the fee paid therefor of \$ is deducted from the total fee due for the total months of extension now requested.								
Const	ructive Petition								
	EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).								
Fee C	alculation (37 C.F.R. §	1.16)							
No fee	e is believed to be due	at this time.							
Fee Pa	ayment								
	No fee is to be paid a	at this time.							
	Check in the amount of \$ for The Commissioner is hereby authorized to charge any additional extension of time fee or additional fee for claims due to Deposit Account No. 50-0310.								

ď)

3.

4.

5.

The Commissioner is hereby authorized to charge any additional fees which may be required, including fees due under 37 C.F.R. §§ 1.16 and 1.17, or credit any overpayment to Deposit Account 50-0310.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Bonnie Weiss McLeod

Reg. No. 43,255

Dated: November 12, 2003

CUSTOMER NO. 09629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004 Telephone: (202) 739-3000

Telephone: (202) 739-3000 Facsimile: (202) 739-3001